Anika Therapeutics | ANIK - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 9.31B 104M 2026-03
Agenus USD -221.22M 241.03M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Halozyme Therapeutics USD 192.19M 18.88M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Integra LifeSciences USD 1.04B 673.49M 2026-03
Intrexon USD 61.56M 26.1M 2024-06
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
MacroGenics USD 21.2M 32.13M 2026-03
Merit Medical Systems USD 337.72M 2.02M 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Smith & Nephew USD 2.52B 84M 2025-12
Stryker USD 4.92B 284M 2026-03
Veracyte USD 119.99M 3.99M 2026-03
Xencor USD 82.38M 513K 2026-03
Zimmer Biomet Holdings USD 1.69B 249.3M 2026-03